ACLC 2024

ACLC 2024 Abstract Submission

You're invited to submit your scientific abstract for ACLC 2024! Submissions are now open through June 7, 2024.

Staging and Prognostic Factors Applications

2024 IASLC Staging & Prognostic Factors Group

Apply to join our Staging and Prognostic Factors Group (SPFG) for the 10th Edition of the Staging Project today!

LALCA 2024

Join us at LALCA 2024!

Submit your scientific abstract and register for LALCA 2024 today!

CTSS 2024 Background

2024 IASLC CT Screening Symposium

The CT Screening Symposium is a 1-day, immersive, in-person event featured at WCLC 2024. Learn More!

ACLC 2024 Abstract Submission
2024 IASLC Staging & Prognostic Factors Group
Join us at LALCA 2024!
2024 IASLC CT Screening Symposium

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

ILCN In Focus

IASLC's Annual Report 2023

2023 was a year of growth focused on expanding our projects and providing our community with more resources than ever before. Read our full report below. 

Strategic Plan 3 Pillars

IASLC's Visionary Strategic Plan for the Next Five Years

In the ever-evolving landscape of lung cancer research and patient care, we have embarked on a transformative journey by unveiling a new strategic plan that redefines its mission and objectives for the next five years.

IASLC Position Statement on the Documentation of Tobacco Use in Cancer Clinical Trials

The IASLC TCSC Committee recently issued an official position statement on the documentation of tobacco use in clinical trials. They note in recent years, there has been growing awareness of the negative impact of tobacco use on clinical outcomes for cancer patients. The 2014 U.S. Surgeon General’s report compiled compelling evidence that cigarette smoking by cancer patients and survivors causes adverse outcomes, including increased all-cause mortality, cancer-specific mortality, and increased risk of a second primary cancer. Furthermore, smoking clearly affects survival and the toxicity of cancer treatments, and these endpoints serve as the primary or secondary objectives of virtually all clinical trials. As a result, it is critical that smoking information be collected and available for analysis to accurately assess the benefits and harms of cancer treatment in clinical trials.

STARS

IASLC's STARS Program

The STARS Program (Supportive Training for Advocates on Research & Science) was formed in 2019 to address this need. A collaboration composed of patient and professional lung cancer research advocates and lung cancer advocacy organizations designed STARS to help patient advocates evolve into patient research advocates (PRAs), increasing the number of PRAs equipped to provide accurate scientific translation in their online or real-life groups for people living with lung cancer, and enabling more people to provide the patient perspective for lung cancer research and policy. 

biomarker test report cover

Resources for Reading & Understanding Biomarker Test Results

Biomarker test results are crucial for lung cancer patients to understand, but they are difficult to read due to their complexity. The Advanced Practitioner Society for Hematology and Oncology, the Association of Community Cancer Centers,  the Association for Molecular Pathology, and LUNGevity Foundation created basic and comprehensive education for ALL non-small cell lung cancer patients to understand their results. Materials are available in English and Spanish. Learn more.

IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

IASLC's Atlas of Molecular Testing for Targeted Therapy in Lung Cancer

The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective. 
 

IASLC Partners for Thoracic Cancer Care

IASLC's Corporate Roundtable

Born from feedback received during meetings with our Corporate Partners in 2022, the IASLC Partners for Thoracic Cancer Care brings IASLC leadership and Roundtable Member Representatives together to collaborate on solutions to big-picture challenges facing those working to conquer lung cancer and other thoracic malignancies. 

Our Impact

11,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide within the 21st century.

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Lung Cancer Policy Network Map

Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
20.121
JTO Impact Factor
8K+
Members

Lung Cancer Policy Network Map

Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

IASLC Neoadjuvant Therapy in Lung Cancers Initiatives

The IASLC is working to address key knowledge gaps in clinical practice related to the use of neoadjuvant therapies in lung cancer through the establishment of the IASLC Neoadjuvant Therapy in Lung Cancers Initiative. These projects aim to knowledge gaps by providing clear definitions and guidance for the lung cancer community to rely on , with the ultimate goal of establishing pathologic response in surgical resection specimens following neoadjuvant therapies (MPR and pCR) as predictors of long-term clinical benefit in patients with stages I to III lung cancers.

In numbers

11,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide in the 21st century.
45
Years Experience
15K
Number of Research Awards Funded
20.4
JTO Impact Factor
8K+
Members
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. 

JTO

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

May 08, 2022